OS Therapies to Participate in Upcoming Investor Conferences in September 2025
OS Therapies (NYSE American: OSTX), a clinical-stage cancer immunotherapy and antibody drug conjugate biotech company, has announced its participation in three major investor conferences in September 2025. The company will attend the Cantor Global Healthcare Conference (Sept 3-5), the H.C. Wainwright Global Investment Conference (Sept 8-10), and the Lake Street Capital Markets BIG9 Conference (Sept 11).
Management will be available for meetings with institutional investors and brokers at all events, with a pre-recorded presentation available for H.C. Wainwright conference participants.
OS Therapies (NYSE American: OSTX), una biotech in fase clinica specializzata in immunoterapie oncologiche e conjugati anticorpo-farmaco, ha confermato la partecipazione a tre importanti conferenze per investitori nel settembre 2025. La società sarà presente al Cantor Global Healthcare Conference (3-5 settembre), al H.C. Wainwright Global Investment Conference (8-10 settembre) e al Lake Street Capital Markets BIG9 Conference (11 settembre).
La direzione sarà disponibile per incontri con investitori istituzionali e broker in tutti gli eventi; per i partecipanti al convegno H.C. Wainwright sarà inoltre disponibile una presentazione preregistrata.
OS Therapies (NYSE American: OSTX), una biotecnológica en fase clínica centrada en inmunoterapias contra el cáncer y conjugados anticuerpo-fármaco, ha anunciado su participación en tres importantes conferencias para inversores en septiembre de 2025. La compañía asistirá al Cantor Global Healthcare Conference (3-5 de septiembre), al H.C. Wainwright Global Investment Conference (8-10 de septiembre) y al Lake Street Capital Markets BIG9 Conference (11 de septiembre).
La dirección estará disponible para reuniones con inversores institucionales y brokers en todos los eventos; además, para los asistentes a H.C. Wainwright habrá una presentación pregrabada.
OS Therapies (NYSE American: OSTX)는 임상 단계의 암 면역치료제 및 항체-약물 접합체(ADC) 개발 바이오텍으로, 2025년 9월에 열리는 세 건의 주요 투자자 콘퍼런스 참가를 발표했습니다. 회사는 Cantor Global Healthcare Conference(9월 3–5일), H.C. Wainwright Global Investment Conference(9월 8–10일), Lake Street Capital Markets BIG9 Conference(9월 11일)에 참석할 예정입니다.
경영진은 모든 행사에서 기관 투자자 및 중개인과의 미팅에 응할 예정이며, H.C. Wainwright 참석자들을 위해 사전 녹화된 프레젠테이션도 제공됩니다.
OS Therapies (NYSE American: OSTX), une société biotech en phase clinique spécialisée dans l'immunothérapie contre le cancer et les conjugués anticorps-médicament, a annoncé sa participation à trois grandes conférences investisseurs en septembre 2025. La société assistera au Cantor Global Healthcare Conference (3-5 septembre), au H.C. Wainwright Global Investment Conference (8-10 septembre) et au Lake Street Capital Markets BIG9 Conference (11 septembre).
La direction sera disponible pour des réunions avec des investisseurs institutionnels et des courtiers lors de tous les événements ; une présentation préenregistrée sera également mise à disposition des participants à la conférence H.C. Wainwright.
OS Therapies (NYSE American: OSTX), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Krebsimmuntherapien und Antikörper-Wirkstoff-Konjugate spezialisiert hat, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im September 2025 angekündigt. Das Unternehmen wird an der Cantor Global Healthcare Conference (3.–5. Sept.), der H.C. Wainwright Global Investment Conference (8.–10. Sept.) und der Lake Street Capital Markets BIG9 Conference (11. Sept.) teilnehmen.
Das Management steht bei allen Veranstaltungen für Gespräche mit institutionellen Investoren und Brokern zur Verfügung; für Teilnehmer der H.C. Wainwright-Konferenz wird zudem eine vorab aufgezeichnete Präsentation bereitgestellt.
- None.
- None.
New York, New York--(Newsfile Corp. - September 3, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will participate in the upcoming investor conferences:
- Cantor Global Healthcare Conference 2025 being held September 3-5, 2025 in New York City. Management will be available for meetings with institutional investors and brokers
- H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York City. A pre-recorded presentation is available for conference participants and management will be available for meetings with institutional investors
- Lake Street Capital Markets 9th Annual Best Ideas Growth (BIG9) Conference being held on September 11, 2025 in New York City. Management will be available for meetings with institutional investors
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the U.S. FDA and other risks and uncertainties described in "Risk Factors" in the Company's most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
OS Therapies Contact Information:
Investor Relations
Harrison Seidner, PhD
WaterSeid Partners
OSTX@waterseid.com
Public Relations
Stephanie Chen
Elev8 New Media
stephanie@elev8newmedia.com
https://x.com/OSTherapies
https://www.instagram.com/ostherapies/
https://www.facebook.com/OSTherapies/
https://www.linkedin.com/company/os-therapies/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/264920
FAQ
When is OS Therapies (OSTX) presenting at the Cantor Global Healthcare Conference 2025?
Where can investors access OS Therapies' (OSTX) presentation for the H.C. Wainwright conference?
Which investor conferences is OS Therapies (OSTX) attending in September 2025?
What type of company is OS Therapies (OSTX)?
